CVS Health's (CVS) 2025 appears "less certain" now that the healthcare company has withdrawn its 2024 guidance and announced changes in leadership, RBC Capital Markets said in a note Friday.
The investment firm said it was lowering its Q4 earnings estimate to $0.75 from $1.66 previously to reflect the company's Q3 results and "persistent utilization headwinds." The Q4 forecast is based on an elevated medical loss ratio, or MLR, estimate of 95.7%, up from 92.1% previously, RBC said.
RBC slashed its 2025 earnings outlook to $5.71 from $7.33 based on a MLR estimate of 92.2%, up from 89.7% earlier.
"With premium deficiency reserves recorded in the quarter, utilization is higher than previously expected, prompting investor concerns around 2025 pricing and utilization," RBC said in its note.
The firm reiterated an outperform rating on the stock and cut its price target to $58 from $68.
Price: 52.97, Change: -2.13, Percent Change: -3.86
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。